SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Neuland Laboratories - Quaterly Results

08 Nov 2025 Evaluate
The turnover soared 65.44% to Rs. 5142.73 millions for the September 2025 quarter as compared to Rs. 3108.44 millions during the corresponding quarter last year.The company almost doubled its revenue to Rs. 964.60 millions  from Rs. 319.58 millions in the quarter ended September 2025.The company reported a good operating profit of 1569.22 millions compared to 656.74 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202509 202409 % Var 202509 202409 % Var 202503 202403 % Var
Sales 5142.73 3108.44 65.44 8070.26 7504.46 7.54 14768.37 15585.80 -5.24
Other Income 17.99 43.32 -58.47 96.55 91.39 5.65 205.09 125.44 63.50
PBIDT 1569.22 656.74 138.94 1990.71 1943.07 2.45 3428.08 4744.65 -27.75
Interest 53.41 10.63 402.45 99.24 37.33 165.85 82.96 139.97 -40.73
PBDT 1515.81 646.11 134.61 1891.47 2112.00 -10.44 4109.16 4604.68 -10.76
Depreciation 225.39 160.73 40.23 427.26 323.52 32.07 655.42 596.99 9.79
PBT 1290.42 485.38 165.86 1464.21 1788.48 -18.13 3453.74 4007.69 -13.82
TAX 325.82 165.80 96.51 362.53 485.49 -25.33 859.48 1011.73 -15.05
Deferred Tax 0.70 43.68 -98.40 -6.26 57.57 -110.87 122.95 15.87 674.73
PAT 964.60 319.58 201.83 1101.68 1302.99 -15.45 2594.26 2995.96 -13.41
Equity 129.01 129.01 0.00 129.01 129.01 0.00 129.01 129.01 0.00
PBIDTM(%) 30.51 21.13 44.42 24.67 25.89 -4.73 23.21 30.44 -23.75

Neuland Laboratories Share Price

17174.30 214.35 (1.26%)
09-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1779.40
Dr. Reddys Lab 1268.75
Cipla 1376.75
Zydus Lifesciences 1105.75
Lupin 2263.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×